Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Toyoaki Hida"'
Autor:
Alice T. Shaw, Yuankai Shi, Pan-Chyr Yang, Keith D. Wilner, Tommaso De Pas, Vera Hirsh, Javier de Castro Carpeño, Pasi A. Jänne, Jean-Charles Soria, Benjamin Solomon, Anna Polli, Fiona H Blackhall, Arlene Reisman, D. Ross Camidge, Tony Mok, Dong Wan Kim, Silvana Lanzalone, Toyoaki Hida, Shrividya Iyer
Publikováno v:
ESMO Open
Blackhall, F, Ross Camidge, D, Shaw, A T, Soria, J C, Solomon, B J, Mok, T, Hirsh, V, Jänne, P A, Shi, Y, Yang, P C, De Pas, T, Hida, T, De Castro Carpeño, J, Lanzalone, S, Polli, A, Iyer, S, Reisman, A, Wilner, K D & Kim, D W 2017, ' Final results of the large-scale multinational trial PROFILE 1005 : Efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer ', ESMO Open, vol. 2, no. 3, e000219 . https://doi.org/10.1136/esmoopen-2017-000219
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Blackhall, F, Ross Camidge, D, Shaw, A T, Soria, J C, Solomon, B J, Mok, T, Hirsh, V, Jänne, P A, Shi, Y, Yang, P C, De Pas, T, Hida, T, De Castro Carpeño, J, Lanzalone, S, Polli, A, Iyer, S, Reisman, A, Wilner, K D & Kim, D W 2017, ' Final results of the large-scale multinational trial PROFILE 1005 : Efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer ', ESMO Open, vol. 2, no. 3, e000219 . https://doi.org/10.1136/esmoopen-2017-000219
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Purpose Crizotinib is a potent, orally administered tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC). We report final results from PROFILE 1005, the largest
Autor:
Kaoru Kubota, Toshiaki Takahashi, Kazuo Kasahara, Kaoru Nakanishi, Toyoaki Hida, Makoto Nishio, Kazuto Nishio, Isamu Okamoto, Shiro Akinaga, Kazuhiko Nakagawa, Koichi Azuma, Taizo Hirata, Nobuyuki Yamamoto, Tomonori Hirashima, Hiroshige Yoshioka, Tetsuya Mitsudomi
Publikováno v:
ESMO Open
Background Patients with epidermal growth factor receptor (EGFR) activation mutation-positive non-small-cell lung cancer (NSCLC) respond well to EGFR tyrosine kinase inhibitors (EGFR-TKIs), but eventually become resistant in most cases. The hepatocyt